Who is sponsoring NCT00541853?

NCT00541853 is sponsored by Kyorin University.

What condition does NCT00541853 study?

NCT00541853 studies Kidney, Polycystic, Autosomal Dominant.

What drugs are being tested in NCT00541853?

Interventions: Candesartan, Candesartan and Cilnidipine, Candesartan plus non-CCB agents.

What is the status of NCT00541853?

NCT00541853 is currently UNKNOWN.

Last reviewed 2007-10-17 · How we verify

Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients

NCT00541853 Phase 4 UNKNOWN

This study examines the safety and efficacy of calcium channel blocker (CCB) in the treatment of hypertension of Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients. Angiotensin receptor blocker (ARB) was shown to have kidney protecting effects in patients with renal diseases including ADPKD, glomerulonephritis and diabetic nephropathy. In case whose blood pressure is not normalized by ARB alone, CCB is selected additionally. Recent research suggests genetic calcium channel disorder is responsible for the progression of ADPKD. It is not examined clinically if CCB treatment has any harmful effect to patients with ADPKD. This study examines the safety of Cilnidipine (CCB) in the ADPKD patients whose blood pressure is not controlled under 130/85 mmHg by Candesartan (ARB) alone.

Details

Lead sponsor	Kyorin University
Phase	Phase 4
Status	UNKNOWN
Enrolment	150
Start date	2007-12
Completion	2012-11

Conditions

Kidney, Polycystic, Autosomal Dominant

Interventions

Candesartan
Candesartan and Cilnidipine
Candesartan plus non-CCB agents

Primary outcomes

Kidney Volume measured by MRI. — Every year

Countries

Japan